CN115340554B - 一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 - Google Patents
一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 Download PDFInfo
- Publication number
- CN115340554B CN115340554B CN202210790470.7A CN202210790470A CN115340554B CN 115340554 B CN115340554 B CN 115340554B CN 202210790470 A CN202210790470 A CN 202210790470A CN 115340554 B CN115340554 B CN 115340554B
- Authority
- CN
- China
- Prior art keywords
- pyrazolopyrimidine compound
- fluorescent probe
- tpp
- pyrazolopyrimidine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 64
- -1 Pyrazolopyrimidine compound Chemical class 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000002632 lipids Chemical class 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000003384 imaging method Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- QPZYPAMYHBOUTC-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]pyrazole-3-carbonitrile Chemical compound NC1=CC(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl QPZYPAMYHBOUTC-UHFFFAOYSA-N 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 11
- 239000011630 iodine Substances 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- LHEUSIVHVNCTMS-UHFFFAOYSA-N 2-(5-thiophen-2-ylthiophen-2-yl)acetaldehyde Chemical compound S1C(=CC=C1CC=O)C=1SC=CC1 LHEUSIVHVNCTMS-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000001917 fluorescence detection Methods 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000001953 sensory effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 1
- 238000006862 quantum yield reaction Methods 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 7
- 239000012528 membrane Substances 0.000 abstract description 6
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 5
- 230000035699 permeability Effects 0.000 abstract description 4
- 238000005424 photoluminescence Methods 0.000 abstract description 4
- 238000010791 quenching Methods 0.000 abstract description 4
- 239000012472 biological sample Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
- 235000019345 sodium thiosulphate Nutrition 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 229940043267 rhodamine b Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WRBQTRDKZJYLQB-UHFFFAOYSA-N CC1=NC(C2=CC=C(C3=CC=CS3)S2)=C(C(C#N)=NN2C(C(Cl)=CC(C(F)(F)F)=C3)=C3Cl)C2=N1 Chemical compound CC1=NC(C2=CC=C(C3=CC=CS3)S2)=C(C(C#N)=NN2C(C(Cl)=CC(C(F)(F)F)=C3)=C3Cl)C2=N1 WRBQTRDKZJYLQB-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1074—Heterocyclic compounds characterised by ligands containing more than three nitrogen atoms as heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1092—Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
技术领域
本发明属于有机发光材料的技术领域,更具体地,涉及一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用。
背景技术
吡唑并嘧啶是一种重要的含氮稠环类化合物,具有广泛的生物活性。其在农药、医药领域中广泛的应用,被用作抗癌药物、酶抑制剂、农用杀菌剂等(Nature,2018,560,192-197;J.Med.Chem.,2020,63,6144-6163;J.Agri.Food Chem.,2021,69,11395-11405.)。但以分子骨架为吡唑并嘧啶的有机发光材料尚未有报道。
脂滴(Lipid droplet)是动植物维持脂质和能量稳态的关键细胞器。其由磷脂单分子表层和中性脂内核形成,膜上镶嵌有多种膜蛋白。脂滴的主要功能是细胞内中性脂的主要存贮场所,动态调节细胞的能量平衡,膜的运输、蛋白降解、组蛋白存储、新陈代谢、病毒识别等生理活动。近年来,越来越多的研究揭示了脂滴具有更多的生理功能,例如抗菌免疫能力,促进药物积累和激活的能力等功能(Nat.Rev.Gastroenterol.Hepatol.,2017,14,343;Cell,2018,174,700;Science,2020,370,8085;Nat.Chem.Biol.,2020,16,206-213.)。目前,检测脂滴的方法主要包括免疫组织法、拉曼散射法、核磁共振法和荧光成像法。与其它方法相比,荧光成像法具有操作简便、灵敏度高、易于直接观察等优势,受到越来越多科学家的青睐。因此,利用荧光探针揭示脂滴相关疾病具有重要的意义。
当前市场中商业化的脂滴染料有尼罗红(Nile Red)和BODIPY系列等,这些商业化的染料存在着孵化时间长、斯托克斯位移小、清洗过程繁琐、聚集诱导荧光淬灭(ACQ)等劣势。因此,开发新型高选择性、高荧光量子产率、抗光漂白的荧光探针在生命科学领域具有重要意义。
发明内容
针对上述现有的技术问题,本发明的目的在于通过分子设计,提供一种吡唑并嘧啶化合物,所述吡唑并嘧啶化合物具有明显的光致发光特性及抑制荧光自猝灭的性质,还具有高荧光量子产率及高光稳定性,可作为一种新型的有机发光材料。
本发明的另一个目的在于提供上述吡唑并嘧啶化合物在作为荧光探针中的应用。
本发明的再一目的在于提供上述吡唑并嘧啶化合物的制备方法。
为了实现上述目的,本发明是通过以下技术方案予以实现的:
一种吡唑并嘧啶化合物,其化学名称为4-((2,2'-联噻吩)-5-基)-1-(2,6-二氯-4-三氟甲基苯基)-6-甲基-1H-吡唑并[3,4-d]嘧啶-3-甲腈,所述吡唑并嘧啶化合物的结构式如式(Ⅰ)所示:
发明人团队通过分子设计,意外地发现了一种具有明显光致发光特性的吡唑并嘧啶化合物,所述吡唑并嘧啶化合物具有高荧光量子产率(ΦF>0.99)及高光稳定性,可作为一种新型的有机发光材料。进一步地,发明人在探索该吡唑并嘧啶化合物的应用时,意外地发现,该吡唑并嘧啶化合物可作为荧光探针对生物体内的脂滴具有优异的靶向能力,对生物样品具有孵育时间短、膜通透性、高荧光量子产率、高对比度成像及高光稳定性的特点,优于商品化的荧光探针Nile Red和rhodamine B。同时,所述吡唑并嘧啶化合物的细胞毒性低,生物相容性好,作为荧光探针时,分子整体为电中性,可消除背景干扰。
进一步地,本发明还提供了上述吡唑并嘧啶化合物的制备方法,具体是,在碘催化剂存在下,将5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑、2,2-联噻吩-5-乙醛、乙腈和溶剂混合加热,经提取后处理后,得到所述吡唑并嘧啶化合物,其反应式如下:
优选地,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和2,2-联噻吩-5-乙醛摩尔比为1:(1~2)。
进一步优选地,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和2,2-联噻吩-5-乙醛的摩尔比为1:2。
优选地,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和乙腈的摩尔比为1:(1~2)。
进一步优选地,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和乙腈的摩尔比为1:2。
优选地,所述溶剂可以本领域常用的有机溶剂,例如是甲苯、氯苯、1,4-二氧六环、1,2-二氯乙烷、乙腈等。
溶剂的用量通常是反应物用量的数十倍至数百倍以上。
例如,当乙腈同时作为本发明的反应物和溶剂时,其用量远高于所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑的用量;具体而言,当所述反应溶剂为乙腈时,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和作为溶剂的乙腈的摩尔比为1:(50~300)。
所述碘催化剂可以是本领域常用的碘催化剂,优选为N-碘代丁二酰亚胺、碘单质或碘化氢中的一种或多种。
优选地,所述加热的温度为110~160℃。
进一步优选地,所述加热温度为120℃。
优选地,所述加热的时间为12~48h。
优选地,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和碘催化剂的摩尔比为1:(1.0~2.0)。
优选地,所述提取后处理为将反应产物洗涤,萃取,再经分离纯化,得到所述吡唑并嘧啶化合物。
具体地,本发明提供了一种具体的提取后处理方法:反应结束后,将反应产物冷却至室温,加入硫代硫酸钠溶液进行洗涤,随后采用二氯甲烷或乙酸乙酯进行萃取,有机相减压蒸馏旋干溶剂后得到粗产物,再采用石油醚和乙酸乙酯混合洗脱液进行柱色谱分离得到所述吡唑并嘧啶化合物。
优选地,所述石油醚和乙酸乙酯混合洗脱液中,石油醚与乙酸乙酯的体积比为10:1。
此外,本发明还提供了所述吡唑并嘧啶化合物在作为荧光探针的应用。
进一步地,所述吡唑并嘧啶化合物在作为传感检测生物体系中的脂滴的荧光探针的应用。
进一步地,所述传感检测包括但不限于荧光检测和/或细胞成像。
进一步地,所述吡唑并嘧啶化合物在作为标记或显示细胞或组织中脂滴形态的荧光探针的应用也应在本发明的保护范围之内。
与现有技术相比,本发明具有以下有益效果:
(1)本发明提供了一种吡唑并嘧啶化合物,具有明显的光致发光特性及抑制荧光自猝灭的性质,还具有高荧光量子产率(ΦF>0.99)及高光稳定性,可作为一种新型的有机发光材料。
(2)所述吡唑并嘧啶化合物还可作为一种新型的荧光探针,用于生物体内活细胞的传感检测,该荧光探针在生物体内具有优异的脂滴靶向能力,对生物样品具有孵育时间短、膜通透性、高荧光量子产率、高对比度成像及高光稳定性的特点;此外,该吡唑并嘧啶化合物细胞毒性低,以及具有良好的生物相容性。
(3)本发明还提供了一种吡唑并嘧啶化合物的制备方法,该制备方法操作简单,仅通过一步合成反应即可制得所述吡唑并嘧啶化合物,且后处理过程简单,原料简单易得。
附图说明
图1为实施例1所得目标产物荧光探针TPP的核磁共振氢谱1H NMR。
图2是实施例1所得目标产物荧光探针TPP的核磁共振碳谱13C NMR。
图3是实施例1所得目标产物荧光探针TPP的核磁共振氟谱19F NMR。
图4是实施例1所得目标产物荧光探针TPP的高分辨质谱HRMS。
图5是实施例1所得目标产物荧光探针TPP在溶液里的荧光量子产率图。
图6是实施例1所得目标产物荧光探针TPP和对照探针Nile Red对SF-9细胞的细胞毒性实验图。
图7是实施例1所得目标产物荧光探针TPP和对照探针Nile Red对HCT-8细胞的细胞毒性实验图。
图8是实施例1所得目标产物荧光探针TPP和对照探针Nile Red和Rhodamine B的光稳定性试验图。
图9是实施例1所得目标产物荧光探针TPP和三种商业探针对SF-9细胞中内质网,线粒体和脂滴染色共聚焦图。
图10是实施例1所得目标产物荧光探针TPP和对照探针Nile Red对HCT-8细胞中脂滴染色共聚焦图。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
此外,除非特别说明,以下实施例所用试剂和材料均为市购。
实施例1吡唑并嘧啶荧光探针TPP的制备
本实施例制备的荧光探针TPP的结构式如下:
本实施例荧光探针TPP的具体制备方法如下:
在反应器中加入0.2毫摩尔的5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,0.4毫摩尔的2,2-联噻吩-5-乙醛,3毫升的乙腈,0.3毫摩尔的单质碘。在氧气氛围下,加热到120℃,持续搅拌16小时后,停止加热反应,将反应器冷却至室温,加入硫代硫酸钠溶液洗涤,然后用乙酸乙酯萃取,干燥,减压蒸馏除去有机溶剂获得粗产物,随后采用流动相体积比为10:1的石油醚和乙酸乙酯洗脱液进行柱层析分离,即得上述荧光探针TPP目标产物,产率34%。
本实施例所得产物的核磁共振氢谱数据如图1所示:1H NMR(600MHz,CDCl3)δ8.49(dd,J=4.1,0.8Hz,1H),7.84(s,2H),7.43–7.39(m,2H),7.36(dd,J=5.1,0.8Hz,1H),7.12–7.06(m,1H),2.78(s,3H);
核磁共振碳谱数据如图2所示:13C NMR(151MHz,CDCl3)δ167.8,156.2,154.5,145.3,138.7,136.4,136.3,135.3,134.6(q,J=34.5Hz),134.1,128.3,126.6,126.1(q,J=3.6Hz),125.7,125.6,122.1(q,J=273.8Hz),120.6,113.8,107.1,26.1;
核磁共振氟谱数据如图3所示:19F NMR(565MHz,CDCl3)δ-63.2(s,3F);IR(KBr):3430,2924,2855,1561,1452,1333,1255,1159,1126cm-1;
高分辨质谱数据如图4所示:HRMS(ESI,m/z):[M+H]+calcd.for C22H10Cl2F3N5S2+H,535.9779;found,535.9781。
实施例2
本实施例制备的荧光探针TPP的结构式如下:
本实施例荧光探针TPP的具体制备方法如下:
在反应器中加入0.2毫摩尔的5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,0.4毫摩尔的2,2-联噻吩-5-乙醛,3毫升的乙腈,0.3毫摩尔的N-碘代丁二酰亚胺。在氧气氛围下,加热到120℃,持续搅拌16小时后,停止加热反应,将反应器冷却至室温,加入硫代硫酸钠溶液洗涤,然后用乙酸乙酯萃取,干燥,减压蒸馏除去有机溶剂获得粗产物,随后采用流动相体积比为10:1的石油醚和乙酸乙酯洗脱液进行柱层析分离,即得上述荧光探针TPP目标产物,产率25%。
实施例3
本实施例制备的荧光探针TPP的结构式如下:
本实施例荧光探针TPP的具体制备方法如下:
在反应器中加入0.2毫摩尔的5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,0.4毫摩尔的2,2-联噻吩-5-乙醛,3毫升的乙腈,0.3毫摩尔的单质碘。在氧气氛围下,加热到160℃,持续搅拌12小时后,停止加热反应,将反应器冷却至室温,加入硫代硫酸钠溶液洗涤,然后用乙酸乙酯萃取,干燥,减压蒸馏除去有机溶剂获得粗产物,随后采用流动相体积比为10:1的石油醚和乙酸乙酯洗脱液进行柱层析分离,即得上述荧光探针TPP目标产物,产率28%。
实施例4
本实施例制备的荧光探针TPP的结构式如下:
本实施例荧光探针TPP的具体制备方法如下:
在反应器中加入0.2毫摩尔的5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,0.2毫摩尔的2,2-联噻吩-5-乙醛,3毫升的乙腈,0.3毫摩尔的单质碘。在氧气氛围下,加热到120℃,持续搅拌24小时后,停止加热反应,将反应器冷却至室温,加入硫代硫酸钠溶液洗涤,然后用乙酸乙酯萃取,干燥,减压蒸馏除去有机溶剂获得粗产物,随后采用流动相体积比为10:1的石油醚和乙酸乙酯洗脱液进行柱层析分离,即得上述荧光探针TPP目标产物,产率22%。
实施例5
本实施例制备的荧光探针TPP的结构式如下:
本实施例荧光探针TPP的具体制备方法如下:
在反应器中加入0.2毫摩尔的5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,0.4毫摩尔的2,2-联噻吩-5-乙醛,1毫升的乙腈,1毫升甲苯,0.3毫摩尔的单质碘。在氧气氛围下,加热到120℃,持续搅拌24小时后,停止加热反应,将反应器冷却至室温,加入硫代硫酸钠溶液洗涤,然后用乙酸乙酯萃取,干燥,减压蒸馏除去有机溶剂获得粗产物,随后采用流动相体积比为10:1的石油醚和乙酸乙酯洗脱液进行柱层析分离,即得上述荧光探针TPP目标产物,产率30%。
实施例6性能测试
(1)荧光探针TPP的光学性质测试
取实施例1制备的荧光探针TPP溶于DMSO溶剂中配置成浓度为1×10-3mol·L-1的溶液,避光保存在冷冻冰箱里作为测试用的母液。测试紫外吸收光谱和荧光光谱时,取100μL母液转移至10mL容量瓶,然后加入溶剂定容至10mL配置成浓度为1×10-3mol·L-1的待测样品。测试紫外和荧光所使用的的石英比色皿规格是1×1×3cm3。测试荧光探针TPP在有机溶剂中的紫外吸收光谱和荧光发射光谱。
测试结果如图5所示,荧光探针TPP的吸收波长λabs=404nm,发射波长λem=486nm,在乙酸乙酯溶液中,观察到TPP在550nm处有单一发射峰,量子产率ΦF大于0.99。
(2)荧光探针TPP的细胞毒性试验
在实际应用中细胞毒性作为一个重要指标。使用标准的CCK-8方法验证实施例1制备的荧光探针TPP和对照探针Nile Red对SF-9细胞和HCT-8细胞毒性。结果如图6和图7所示,实施例1制备的荧光探针TPP对SF-9细胞和HCT-8细胞无明显毒性。因此,荧光探针TPP对生物活细胞是安全的,适用于细胞成像实验。
(3)荧光探针TPP对光稳定性试验
在荧光光谱仪用时间扫描模式(time-scan mode)测试实施例1制备的荧光探针TPP、对照探针Nile Red和Rhodamine B在一段时间内重复激发下的峰值荧光强度,时间梯度设定为10s,时间范围设定为20min,激发波长设定为550nm,监测峰值波长设定为550nm。其中激发波长与峰值波长参考在波长模式下测得的荧光光谱数据,如图8所示,随着时间的增长,荧光探针TPP的峰值荧光强度几乎无变化;而对照探针Nile Red的峰值荧光强度低于荧光探针TPP,且峰值荧光强度不稳定;对照探针Rhodamine B的峰值荧光强度逐渐降低;上述说明本申请制备的荧光探针TPP具有优异的光稳定性。
(4)荧光探针TPP对SF-9细胞中荧光成像
为了证实实施例1制备的荧光探针TPP能够靶向在细胞内的脂滴部位,将10μL实施例2中制备的荧光探针TPP(λex=405nm)的DMSO溶液母液加入到育有SF-9细胞的培养液中,37℃条件下在培养箱中培养(孵育时间)20min,使用激光扫描共焦显微镜捕获SF-9细胞的荧光共焦图像。然后分别与商业染料Nile Red(脂滴商染,λex=560nm)、Mito tracker(线粒体商染,λex=570nm)和ER tracker(内质网商染,λex=587nm)共培养20min,用PBS缓冲溶液洗2遍,分别在各自的激发波长之下进行激光共聚焦显影。
如图9所示,在脂滴区域,红色通道与绿色通道重叠良好,荧光探针TPP与Nile Red的皮尔逊系数(Rr)大于0.8。可见,荧光探针TPP不仅具有膜通透性,还能够靶向在SF-9细胞内的脂滴部位。
(5)荧光探针TPP对HCT-8细胞中脂滴荧光成像
为了证实荧光探针TPP能够在其他动物细胞内的靶向点亮脂滴部位,将10μL实施例2中制备的荧光探针TPP(λex=405nm)的DMSO溶液母液加入到育有HCT-8细胞的培养液中在培养箱中在37℃条件下培养(孵育时间)20min,使用激光扫描共焦显微镜捕获SF-9细胞的荧光共焦图像。然后与商业染料Nile Red脂滴商染,λex=560nm)共培养20min,用PBS缓冲溶液洗2遍,分别在各自的激发波长之下进行激光共聚焦显影。
如图10所示,在脂滴区域,红色通道与绿色通道重叠良好,荧光探针TPP与NileRed的皮尔逊系数(Rr)大于0.8。可见,荧光探针TPP能够靶向在HCT-8细胞内的脂滴部位。
前述的实例仅是说明性的,用于解释本发明所述方法的一些特征。所附的权利要求旨在要求可以设想的尽可能广的范围,且本文所呈现的实施例为申请人真实试验结果加以论证。因此,申请人的用意是所附的权利要求不被说明本发明的特征的示例的选择限制。在权利要求中所用的一些数值范围也包括了在其之内的子范围,这些范围中的变化也应在可能的情况下解释为被所附的权利要求覆盖。
Claims (9)
2.权利要求1所述吡唑并嘧啶化合物在非疾病治疗和诊断中作为荧光探针的应用。
3.权利要求1所述吡唑并嘧啶化合物在非疾病治疗和诊断中作为传感检测生物体系中的脂滴的荧光探针的应用。
4.根据权利要求3所述应用,其特征在于,所述传感检测为荧光检测和/或细胞成像。
5.权利要求1所述吡唑并嘧啶化合物在非疾病治疗和诊断中作为标记或显示细胞或组织中脂滴形态的荧光探针的应用。
7.根据权利要求6所述制备方法,其特征在于,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和2,2-联噻吩-5-乙醛的摩尔比为1:(1~2)。
8.根据权利要求6所述制备方法,其特征在于,所述5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑和乙腈的摩尔比为1:(1~2)。
9.根据权利要求6所述制备方法,其特征在于,所述加热的温度为110~160℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210790470.7A CN115340554B (zh) | 2022-07-06 | 2022-07-06 | 一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210790470.7A CN115340554B (zh) | 2022-07-06 | 2022-07-06 | 一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115340554A CN115340554A (zh) | 2022-11-15 |
CN115340554B true CN115340554B (zh) | 2023-04-18 |
Family
ID=83947888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210790470.7A Active CN115340554B (zh) | 2022-07-06 | 2022-07-06 | 一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115340554B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108329316A (zh) * | 2017-12-29 | 2018-07-27 | 广西师范学院 | 一种检测镍离子的生物荧光探针及其制备方法 |
CN108822019A (zh) * | 2018-08-21 | 2018-11-16 | 济南大学 | 一种检测脂滴极性的荧光探针及其制备方法和应用 |
CN109912501A (zh) * | 2019-01-15 | 2019-06-21 | 湖南大学 | 一种高选择性且大Stokes位移的酯滴探针及其制备方法和应用 |
CN114292281A (zh) * | 2021-12-22 | 2022-04-08 | 东南大学 | 一种用于实现细胞内脂滴动态成像的小分子荧光探针及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874188B (zh) * | 2022-05-10 | 2023-07-11 | 安徽大学 | 一种含有咔唑-吡啶甲酰肼基的脂滴荧光探针及其制备方法和用途 |
-
2022
- 2022-07-06 CN CN202210790470.7A patent/CN115340554B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108329316A (zh) * | 2017-12-29 | 2018-07-27 | 广西师范学院 | 一种检测镍离子的生物荧光探针及其制备方法 |
CN108822019A (zh) * | 2018-08-21 | 2018-11-16 | 济南大学 | 一种检测脂滴极性的荧光探针及其制备方法和应用 |
CN109912501A (zh) * | 2019-01-15 | 2019-06-21 | 湖南大学 | 一种高选择性且大Stokes位移的酯滴探针及其制备方法和应用 |
CN114292281A (zh) * | 2021-12-22 | 2022-04-08 | 东南大学 | 一种用于实现细胞内脂滴动态成像的小分子荧光探针及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
Guangkai Yao et al..Oxidative Annulation of Aldehydes, 5-Aminopyrazoles, and Nitriles: Synthesis and Applications of Pyrazolo[3,4-d]Pyrimidines.《Adv. Synth. Catal. 》.2023,第1-15页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115340554A (zh) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | A novel DCM-NBD conjugate fluorescent probe for discrimination of Cys/Hcy from GSH and its bioimaging applications in living cells and animals | |
CN107089937B (zh) | 线粒体靶向测定粘度的荧光探针及其制备方法和应用 | |
Gu et al. | Detection of endogenous hydrogen peroxide in living cells with para-nitrophenyl oxoacetyl rhodamine as turn-on mitochondria-targeted fluorescent probe | |
Berger et al. | Applications of triarylborane materials in cell imaging and sensing of bio-relevant molecules such as DNA, RNA, and proteins | |
Li et al. | A near-infrared frequency upconversion probe for nitroreductase detection and hypoxia tumor in vivo imaging | |
Tong et al. | A ratiometric fluorescent pH probe based on keto–enol tautomerization for imaging of living cells in extreme acidity | |
CN110698454B (zh) | 一种异佛尔酮类硫化氢荧光探针及其制备方法与应用 | |
CN112694431B (zh) | 超敏感荧光探针检验细菌中硝基还原酶及在细菌感染应用 | |
CN1902490B (zh) | 生物分子检测方法及其所用的标记染料和标记试剂盒 | |
Xu et al. | A fast-responsive two-photon fluorescent turn-on probe for nitroreductase and its bioimaging application in living tissues | |
Zhang et al. | Red emissive fluorescent probe for the rapid detection of selenocysteine | |
Saito et al. | Synthesis of boradiazaindacene–imidazopyrazinone conjugate as lipophilic and yellow-chemiluminescent chemosensor for superoxide radical anion | |
KR20180083806A (ko) | pH 검출용 염료 화합물, 이를 이용한 필름 및 키트 | |
CN105906619B (zh) | 一种双光子荧光探针及其制备方法和用途 | |
CN115340554B (zh) | 一种吡唑并嘧啶化合物及其制备方法和作为荧光探针的应用 | |
CN111533761B (zh) | 一类具有细胞器或蛋白质靶向功能的比率型pH探针及应用 | |
CN109503550B (zh) | 2-氮杂芳基-6-取代氨基喹唑啉酮化合物及其制备方法和应用 | |
CN114773305B (zh) | 一种2-2环芳吡喃酮pH荧光比率探针的制备方法及应用 | |
CN110357896A (zh) | 一类化合物及制备与其在检测二价铜离子和强酸pH中的应用 | |
CN114106027B (zh) | 一种氟硼荧光染料-四嗪类荧光探针及其制备方法和用途 | |
CN110669350B (zh) | 一种哌啶基bodipy类红光荧光染料及其制备方法和应用 | |
CN112538089A (zh) | 近红外硅基罗丹明荧光染料、制备方法及其在线粒体脊膜原位免洗成像中的应用 | |
Ou et al. | A robust high selectivity fluorescence turn-on nanoprobe for peroxynitrite detection in inflammatory cells and mice | |
Guo et al. | One-pot synthesis and applications of two asymmetrical benzoxanthene dyes | |
CN113135904B (zh) | 羟自由基近红外荧光分子探针及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |